MA45543A - Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées - Google Patents
Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associéesInfo
- Publication number
- MA45543A MA45543A MA045543A MA45543A MA45543A MA 45543 A MA45543 A MA 45543A MA 045543 A MA045543 A MA 045543A MA 45543 A MA45543 A MA 45543A MA 45543 A MA45543 A MA 45543A
- Authority
- MA
- Morocco
- Prior art keywords
- peptides
- amyloid beta
- beta antibodies
- associated uses
- n3pglu amyloid
- Prior art date
Links
- 102000013455 Amyloid beta-Peptides Human genes 0.000 title 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662357579P | 2016-07-01 | 2016-07-01 | |
| PCT/US2017/038999 WO2018005282A1 (fr) | 2016-07-01 | 2017-06-23 | Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA45543A true MA45543A (fr) | 2019-05-08 |
| MA45543B1 MA45543B1 (fr) | 2023-08-31 |
Family
ID=59295341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA45543A MA45543B1 (fr) | 2016-07-01 | 2017-06-23 | Anticorps anti-peptide bêta-amyloïde n3pglu et leurs utilisations |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US11312763B2 (fr) |
| EP (2) | EP3478712B1 (fr) |
| JP (4) | JP7165588B2 (fr) |
| KR (3) | KR20210024213A (fr) |
| CN (3) | CN114887054A (fr) |
| AU (1) | AU2017291414B2 (fr) |
| BR (1) | BR112018073843A2 (fr) |
| CA (1) | CA3029550C (fr) |
| DK (1) | DK3478712T3 (fr) |
| EA (1) | EA201892690A1 (fr) |
| ES (1) | ES2958508T3 (fr) |
| FI (1) | FI3478712T3 (fr) |
| HR (1) | HRP20230861T1 (fr) |
| HU (1) | HUE062980T2 (fr) |
| IL (1) | IL263788B1 (fr) |
| LT (1) | LT3478712T (fr) |
| MA (1) | MA45543B1 (fr) |
| MD (1) | MD3478712T2 (fr) |
| MX (2) | MX2018016066A (fr) |
| PL (1) | PL3478712T3 (fr) |
| PT (1) | PT3478712T (fr) |
| RS (1) | RS64386B1 (fr) |
| SG (1) | SG11201810371XA (fr) |
| SI (1) | SI3478712T1 (fr) |
| TW (2) | TWI735600B (fr) |
| UA (1) | UA127101C2 (fr) |
| WO (1) | WO2018005282A1 (fr) |
| ZA (1) | ZA201807633B (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
| JOP20190247A1 (ar) | 2017-04-20 | 2019-10-20 | Lilly Co Eli | أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها |
| EP3521308B1 (fr) * | 2018-01-31 | 2024-03-13 | Vivoryon Therapeutics N.V. | Anticorps humanisés et dé-immunisés |
| WO2019169448A1 (fr) * | 2018-03-09 | 2019-09-12 | St Vincent's Institute Of Medical Research | Anticorps multi-spécifiques |
| JP2021532126A (ja) * | 2018-07-24 | 2021-11-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | アルツハイマー病の治療及び予防方法 |
| CN111184725B (zh) * | 2020-02-27 | 2020-12-01 | 慈溪市人民医院医疗健康集团(慈溪市人民医院) | 一种防治脑梗塞的药物制剂及其制备方法 |
| EP4274611A1 (fr) * | 2021-01-11 | 2023-11-15 | Eli Lilly and Company | Anticorps anti-n3pglu bêta-amyloïde et leurs utilisations |
| WO2022251048A1 (fr) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anticorps anti-amyloïde bêta et leurs utilisations |
| KR20240099349A (ko) * | 2021-10-29 | 2024-06-28 | 일라이 릴리 앤드 캄파니 | 인터류킨-34를 표적화하는 화합물 및 방법 |
| WO2023076970A1 (fr) * | 2021-10-29 | 2023-05-04 | Eli Lilly And Company | Composés et procédés ciblant l'interleukine-34 |
| WO2023146818A2 (fr) * | 2022-01-26 | 2023-08-03 | T3D Therapeutics, Inc. | Procédés de traitement de troubles cérébraux liés à l'amyloïde à l'aide de nouveaux composés et d'anticorps |
| WO2023150483A1 (fr) * | 2022-02-03 | 2023-08-10 | Eli Lilly And Company | Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1397539A (en) * | 1920-01-14 | 1921-11-22 | Odell Risdon Moore | Egg-carton |
| AU4178601A (en) | 2000-02-24 | 2001-09-03 | Univ Washington | Humanized antibodies that sequester abeta peptide |
| US7122374B1 (en) | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| EP1523499A2 (fr) | 2002-07-24 | 2005-04-20 | Innogenetics N.V. | Fragments du peptide beta-amyloide en tant que cibles pour la vaccination contre la maladie d'alzheimer |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| SG190665A1 (en) | 2004-07-30 | 2013-06-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
| RS52004B (en) | 2005-12-12 | 2012-04-30 | F. Hoffmann-La Roche Ag | ANTIBODIES AGAINST AMYLOID BETA WITH GLYCOSILATION IN THE VARIABLE REGION |
| EP2325209A3 (fr) | 2006-03-23 | 2011-08-03 | BioArtic Neuroscience AB | Anticorps améliorés sélectifs de protofibrilles et leur utilisation |
| CL2007002070A1 (es) | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
| DK2121754T3 (en) | 2007-01-18 | 2015-02-23 | Lilly Co Eli | Pegylated amyloid BETA FAB |
| PL2182983T3 (pl) * | 2007-07-27 | 2014-10-31 | Janssen Alzheimer Immunotherap | Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta |
| WO2009149487A2 (fr) | 2008-06-12 | 2009-12-17 | Affiris Ag | Composés destinés au traitement de symptômes associés à la maladie de parkinson |
| CA2730073A1 (fr) | 2008-07-09 | 2010-01-14 | University Of Zurich | Procede d'activation de la neurogenese |
| EP3338796A1 (fr) | 2008-07-21 | 2018-06-27 | Probiodrug AG | Dosage d'anticorps de diagnostic |
| CN101397539B (zh) * | 2008-10-14 | 2011-10-05 | 中国人民解放军第三军医大学 | 组织工程组织仿生培养的模拟人体生理应力的施力装置 |
| UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
| US8795664B2 (en) | 2010-06-04 | 2014-08-05 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Monoclonal antibodies targeting amyloid beta oligomers |
| WO2012021475A2 (fr) | 2010-08-12 | 2012-02-16 | Eli Lilly And Company | ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS |
| SI2603523T1 (sl) | 2010-08-12 | 2016-04-29 | Eli Lilly And Company | PROTITELESA PROTI N3pGlu AMILOID BETA PEPTIDU IN NJIHOVE UPORABE |
| US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
| AU2013354968A1 (en) | 2012-12-07 | 2015-07-16 | Joseph Arndt | A method of reducing brain amyloid plaques using anti-AB antibodies |
| TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
| TWI785472B (zh) | 2014-02-08 | 2022-12-01 | 美商建南德克公司 | 治療阿茲海默症之方法 |
| WO2015175769A1 (fr) * | 2014-05-15 | 2015-11-19 | Biogen Ma Inc. | Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques |
| WO2015191825A1 (fr) * | 2014-06-13 | 2015-12-17 | Biogen Ma Inc. | Méthodes pour la détection et la mesure de la protéine beta amyloïde dans des échantillons biologiques |
| JP6201928B2 (ja) * | 2014-08-04 | 2017-09-27 | トヨタ自動車株式会社 | 車両制御装置 |
| TWI570127B (zh) | 2014-09-15 | 2017-02-11 | 美國禮來大藥廠 | 結晶型N-[3-[(4aR,7aS)-2-胺基-6-(5-氟嘧啶-2-基)-4,4a,5,7-四氫吡咯并[3,4-d][1,3]噻嗪-7a-基]-4-氟-苯基]-5-甲氧基-吡嗪-2-甲醯胺、其用途及醫藥組合物 |
| TWI599358B (zh) * | 2014-09-16 | 2017-09-21 | 美國禮來大藥廠 | 組合療法 |
| US10017505B2 (en) | 2014-09-30 | 2018-07-10 | Merck Sharp & Dohme Corp. | Crystalline forms of a BACE inhibitor, compositions, and their use |
| MA41115A (fr) * | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| JOP20170004B1 (ar) | 2016-01-15 | 2022-09-15 | Lilly Co Eli | الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته |
| TWI735600B (zh) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | 抗－N3pGlu類澱粉β肽抗體及其用途 |
-
2017
- 2017-06-16 TW TW106120115A patent/TWI735600B/zh active
- 2017-06-16 TW TW110125726A patent/TWI798751B/zh active
- 2017-06-23 HR HRP20230861TT patent/HRP20230861T1/hr unknown
- 2017-06-23 PL PL17736841.2T patent/PL3478712T3/pl unknown
- 2017-06-23 US US16/310,629 patent/US11312763B2/en active Active
- 2017-06-23 KR KR1020217005333A patent/KR20210024213A/ko not_active IP Right Cessation
- 2017-06-23 JP JP2018567740A patent/JP7165588B2/ja active Active
- 2017-06-23 KR KR1020187037757A patent/KR102221402B1/ko active IP Right Grant
- 2017-06-23 BR BR112018073843-3A patent/BR112018073843A2/pt unknown
- 2017-06-23 SG SG11201810371XA patent/SG11201810371XA/en unknown
- 2017-06-23 EP EP17736841.2A patent/EP3478712B1/fr active Active
- 2017-06-23 UA UAA201811726A patent/UA127101C2/uk unknown
- 2017-06-23 EP EP23176986.0A patent/EP4272828A3/fr active Pending
- 2017-06-23 MX MX2018016066A patent/MX2018016066A/es unknown
- 2017-06-23 AU AU2017291414A patent/AU2017291414B2/en active Active
- 2017-06-23 EA EA201892690A patent/EA201892690A1/ru unknown
- 2017-06-23 ES ES17736841T patent/ES2958508T3/es active Active
- 2017-06-23 CA CA3029550A patent/CA3029550C/fr active Active
- 2017-06-23 IL IL263788A patent/IL263788B1/en unknown
- 2017-06-23 WO PCT/US2017/038999 patent/WO2018005282A1/fr unknown
- 2017-06-23 FI FIEP17736841.2T patent/FI3478712T3/fi active
- 2017-06-23 HU HUE17736841A patent/HUE062980T2/hu unknown
- 2017-06-23 MD MDE20190551T patent/MD3478712T2/ro unknown
- 2017-06-23 SI SI201731389T patent/SI3478712T1/sl unknown
- 2017-06-23 KR KR1020237004025A patent/KR20230021773A/ko not_active Application Discontinuation
- 2017-06-23 MA MA45543A patent/MA45543B1/fr unknown
- 2017-06-23 PT PT177368412T patent/PT3478712T/pt unknown
- 2017-06-23 CN CN202210683585.6A patent/CN114887054A/zh active Pending
- 2017-06-23 LT LTEPPCT/US2017/038999T patent/LT3478712T/lt unknown
- 2017-06-23 RS RS20230595A patent/RS64386B1/sr unknown
- 2017-06-23 CN CN202210683554.0A patent/CN114917338A/zh active Pending
- 2017-06-23 DK DK17736841.2T patent/DK3478712T3/da active
- 2017-06-23 CN CN201780040635.6A patent/CN109415433A/zh active Pending
-
2018
- 2018-11-13 ZA ZA2018/07633A patent/ZA201807633B/en unknown
- 2018-12-18 MX MX2023001299A patent/MX2023001299A/es unknown
-
2020
- 2020-12-03 JP JP2020201050A patent/JP7241058B2/ja active Active
- 2020-12-03 JP JP2020201051A patent/JP2021059547A/ja active Pending
-
2022
- 2022-04-01 US US17/711,099 patent/US20220235122A1/en active Pending
-
2023
- 2023-06-06 JP JP2023093033A patent/JP2023123503A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA45543A (fr) | Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées | |
| MA47694A (fr) | Anticorps anti-tigit | |
| MA49034A (fr) | Anticorps anti-lag3 | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA47268A (fr) | Anticorps anti-gpc3 | |
| MA49537A (fr) | Anticorps anti-lag3 et leurs utilisations | |
| KR102162129B9 (ko) | 항-갈렉틴-9 항체 및 이의 용도 | |
| MA45235A (fr) | Anticorps anti-c5 et leurs utilisations | |
| MA46708A (fr) | Anticorps anti-pd1 et leurs utilisations | |
| MA47789A (fr) | Anticorps anti-phf-tau et leurs utilisations | |
| MA53434A (fr) | Anticorps anti-tigit | |
| MA45125A (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA52884A (fr) | Anticorps anti-il-11 | |
| MA53184A (fr) | Anticorps anti-ox40 et leurs utilisations | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| MA42935A (fr) | Anticorps bispécifiques anti-cd3 optimisés et leurs utilisations | |
| KR20180084817A (ko) | 항-siglec-9 항체 및 이의 이용 방법 | |
| DK3307274T3 (da) | Anti-cd123-antistoffer og konjugater deraf | |
| MA45231A (fr) | Anticorps anti-ige | |
| MA46272A (fr) | Anticorps anti-cd27 | |
| MA47472A (fr) | Anticorps | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA49886A (fr) | Anticorps anti-par2 et leurs utilisations |